YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

Fixed Drug Eruption Induced by Topical Olopatadine Ophthalmic Solution

dc.authorscopusid 17134049200
dc.authorscopusid 26425048800
dc.authorscopusid 23008611500
dc.authorscopusid 26646261000
dc.authorscopusid 8941649100
dc.authorwosid Karadag, Ayse/V-7974-2018
dc.contributor.author Bilgili, S. G.
dc.contributor.author Karadag, A. S.
dc.contributor.author Karadag, R.
dc.contributor.author Bulut, G.
dc.contributor.author Calka, O.
dc.date.accessioned 2025-05-10T16:47:14Z
dc.date.available 2025-05-10T16:47:14Z
dc.date.issued 2012
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp [Bilgili, S. G.; Karadag, A. S.; Calka, O.] Yuzuncu Yil Univ, Dept Dermatol, TR-65100 Van, Turkey; [Karadag, R.] Yuzuncu Yil Univ, Dept Ophtalmol, TR-65100 Van, Turkey; [Bulut, G.] Cardiovasc Training & Res Hosp, Dept Pathol, Van, Turkey en_US
dc.description.abstract Fixed drug eruption (FDE) usually develops after oral administration and is described as a cutaneous reaction recurring at the same location each time the drug is taken. Olopatadine is both a H I histamine receptor antagonist and a mast cell stabilizer, indicated for the treatment of allergic conjunctivitis. Here, we report a 14-year-old male patient who developed FDE localised on the lateral side of periorbital rim bilaterally, whilst applying olopatadine 0.1% ophthalmic solution for the treatment of allergic conjunctivitis. As far as we know, FDE due to olopatadine has not been previously reported in the literature. We deem it appropriate to report this case because FDE that results from the application of topical drugs is a rare event in the literature. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.doi 10.1177/0960327112440112
dc.identifier.endpage 1294 en_US
dc.identifier.issn 0960-3271
dc.identifier.issn 1477-0903
dc.identifier.issue 12 en_US
dc.identifier.pmid 22531967
dc.identifier.scopus 2-s2.0-84871604488
dc.identifier.scopusquality Q2
dc.identifier.startpage 1292 en_US
dc.identifier.uri https://doi.org/10.1177/0960327112440112
dc.identifier.uri https://hdl.handle.net/20.500.14720/1396
dc.identifier.volume 31 en_US
dc.identifier.wos WOS:000311762100012
dc.identifier.wosquality Q3
dc.language.iso en en_US
dc.publisher Sage Publications Ltd en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Fixed Drug Eruption en_US
dc.subject Topically en_US
dc.subject Olopatadine en_US
dc.subject Antihistaminic Drug en_US
dc.title Fixed Drug Eruption Induced by Topical Olopatadine Ophthalmic Solution en_US
dc.type Article en_US

Files